Page 305 - Optimalisasi Peran Sains dan Teknologi Untuk Mewujudkan Smart City

Gnecchi, M., Danieli, P., & Cervio, E. (2012). Mesenchymal stem cell
therapy for heart disease. Vascular pharmacology, 57(1), 48-55.

Hartman, M. E., Dai, D. F., & Laflamme, M. A. (2016). Human
pluripotent stem cells: prospects and challenges as a source of
cardiomyocytes for in vitro modeling and cell-based cardiac
repair. Advanced drug delivery reviews, 96, 3-17.

Hsiao, L. C., & Carr, C. A. (2013). Endogenous cardiac stem cell therapy
for ischemic heart failure. J Clin Exp Cardiol, 11, 007.

Hsieh, P. C., Segers, V. F., Davis, M. E., MacGillivray, C., Gannon, J.,
Molkentin, J. D., & Lee, R. T. (2007). Evidence from a genetic fate-
mapping study that stem cells refresh adult mammalian
cardiomyocytes after injury. Nature medicine, 13(8), 970.

Jastrzebska, E., Tomecka, E., & Jesion, I. (2016). Heart-on-a-chip based
on stem cell biology. Biosensors and Bioelectronics, 75, 67-81.

Konoplyannikov, M., Kalsin, V., Averyanov, A. and Troitsky, A. (2016)
Stem Cell Therapy of IschemicHeart Disease. J. Biomedical Science
and Engineering, 9, 191-215. http://dx.doi.org/10.4236/jbise.
2016.94015

Kubin, T., Po¨ ling, J., Kostin, S., Gajawada, P., Hein, S., Rees, W.,
Wietelmann,A., Tanaka, M., Lo¨ rchner, H., Schimanski, S., et al.
(2011). Oncostatin M isa major mediator of cardiomyocyte
dedifferentiation and remodeling. Cell Stem Cell 9, 420–432.

Laflamme, M.A., Chen, K.Y., Naumova, A.V., Muskheli, V., Fugate, J.A.,
Dupras, S.K., Reinecke, H., Xu, C., Hassanipour, M., Police, S., et al.
(2007). Cardiomyocytes derived from human embryonic stem
cells in pro-survival factors enhance function of infarcted rat
hearts. Nat. Biotechnol. 25 , 1015–1024.

Optimalisasi Peran Sains dan Teknologi untuk Mewujudkan Smart City 289